INVESTOR RELATIONS

Intellia is a leading genome editing company, focused on the development of potentially curative therapeutics utilizing the CRISPR/Cas9 system. The Company’s mission is to develop gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Recent News
Upcoming Events

There are currently no events scheduled.

 
Stock Information
NASDAQ  |  NTLA (Common Stock)
$15.87 + 0.34
Stock chart for: NTLA.O.  Currently trading at $15.87 with a 52 week high of $30.40 and a 52 week low of $11.86.
12/02/16 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
 
IR Contacts

John Graziano
Trout Group, LLC
646-378-2942

Chad Rubin
Trout Group, LLC
646-378-2947